Literature DB >> 12388829

Reduction of arsenate to arsenite in hepatic cytosol.

Balázs Németi1, Zoltán Gregus.   

Abstract

After finding that rat liver mitochondria reduce arsenate (AsV) to the more toxic arsenite (AsIII), it was of interest to know if other cell fractions also carried out this process. Postmitochondrial supernatant (PMSN), isolated from rat liver, reduced AsV to AsIII only in the presence of a thiol. Dithiothreitol (DTT) supported the reduction much more effectively than glutathione. Separation of PMSN into microsome and cytosol revealed that the AsV reducing activity resided in the cytosol. AsV-like oxyanions, e.g., phosphate (P(i)) and vanadate, as well as mercurial thiol reagents inhibited the cytosolic AsV reducing activity, indicating the involvement of a P(i)-utilizing SH enzyme. On searching for a reduction partner, it was found unexpectedly that oxidized pyridine nucleotides (NAD(+) or NADP(+)), but not their reduced forms, increased AsIII formation. Some other purine nucleotide derivatives (e.g., AMP, GMP), but not pyrimidine nucleotides, also increased the rate 2-3-fold. Examination of the effect of nucleosides and nucleobases on AsV reduction yielded dramatic results: purine nucleosides (inosine or guanosine) increased the reduction 80-100-fold, whereas purine bases (hypoxanthine or guanine) decreased it 80-90%. Although the retentate obtained by ultrafiltration of cytosol was almost inactive, its AsV reductase activity could be regained by adding the filtrate or inosine or guanosine to the retentate, indicating that endogenous purine nucleosides were essential for AsV reduction by the cytosol. The hepatic cytosol of mice, hamsters, guinea pigs, and rabbits also exhibited AsV reductase activities in the presence of DTT, which were dramatically enhanced by inosine. Thus, the hepatic cytosol of all tested species can reduce AsV to AsIII. The reduction requires the presence of an appropriate thiol as well as a purine nucleoside (inosine or guanosine) and is inhibited by thiol reagents, the AsV analogue phosphate, and purine bases. Characterization of this AsV reductase activity led us to identification of a cytosolic AsV reductase, which is presented in the accompanying paper.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388829     DOI: 10.1093/toxsci/70.1.4

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  4 in total

1.  shRNA silencing of AS3MT expression minimizes arsenic methylation capacity of HepG2 cells.

Authors:  Zuzana Drobna; Weibing Xing; David J Thomas; Miroslav Stýblo
Journal:  Chem Res Toxicol       Date:  2006-07       Impact factor: 3.739

2.  Targeted cancer cell delivery of arsenate as a reductively activated prodrug.

Authors:  Daniela Cioloboc; Donald M Kurtz
Journal:  J Biol Inorg Chem       Date:  2020-03-18       Impact factor: 3.358

Review 3.  Arsenic, Oxidative Stress and Reproductive System.

Authors:  Felor Zargari; Md Shiblur Rahaman; Robab KazemPour; Mahbobeh Hajirostamlou
Journal:  J Xenobiot       Date:  2022-07-18

4.  Gallic acid and MiADMSA reversed arsenic induced oxidative/nitrosative damage in rat red blood cells.

Authors:  Archna Panghal; Kshirod Bihari Sathua; S J S Flora
Journal:  Heliyon       Date:  2020-02-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.